The FDA recently contacted more than 2,200 sponsors and researchers connected to over 3,000 clinical trials that may be missing required results reporting on ClinicalTrials.gov.
In an FDA News Release on April 13, the agency shared that nearly 30% of studies likely subject to mandatory reporting requirements still have missing clinical trial results. That should grab the attention of every pharmaceutical, biotechnology, and research organization managing active studies.
This outreach signals growing pressure around transparency expectations. Pharmaceutical and biotech sponsors that fall behind may face formal notices of noncompliance, financial penalties, and reputational challenges. Delayed reporting and missing clinical trial results also creates gaps in the public record that can impact trust with regulators, researchers, physicians, and patients.
FDA Commissioner Marty Makary said it clearly, “Those sponsoring clinical trials have an ethical obligation to make results public regardless of the data’s influence on the company’s share price.”
In previous FDA communications, they have stated that the civil monetary penalties for non-compliance can be as high as $13,237 per day for missing clinical trial results.
Why teams are falling behind
Clinical trial registration and results disclosure can quickly become operational headaches. Many teams are juggling things like:
- Manual data entry into ClinicalTrials.gov
- Disconnected workflows across global registries
- Inconsistent source documents
- Slow approval cycles
- Limited internal bandwidth
- Growing global transparency expectations
ClinicalTrials.gov is only one piece of the equation. Teams are also managing requirements tied to EU Clinical Trial Regulation, EMA Policy 0070, Health Canada PRCI, and many additional global disclosure requirements. As portfolios expand, it’s in our experience that these manual processes become harder to maintain.
A much bigger operational issue
This FDA announcement points to a larger shift where transparency is getting much more attention from regulators, and outdated workflows are creating unnecessary risk. In many organizations, the responsibility for clinical trial registration and results disclosure often falls on one person or a very small team already balancing competing priorities. They may be managing ClinicalTrials.gov updates, global registry submissions, results reporting deadlines, protocol amendments, internal approvals, and questions from cross-functional teams, all while relying on spreadsheets, email chains, and manual data entry.
That creates a fragile process.
If one deadline gets missed, one approval gets delayed, or one source document contains outdated information, the ripple effects can be significant. Teams can find themselves scrambling to correct records, respond to regulators, and explain why reporting timelines slipped.
Multiply this across the thousands of sponsor and clinical trials and the situation becomes much more dire.
To reiterate the urgency of missing clinical trial results, Tracy Beth Hoeg, M.D., Ph.D., Acting Director of the Center for Drug Evaluation and Research, said this in the the April FDA News Release: “I fully support this new initiative to increase the prompt publication—as required by law—of results information from interventional studies of the medical products we regulate. We hope that the thousands of messages sent to sponsors and investigators reminding them to publicly report their findings will improve patient safety and keep researchers and the public better informed of benefits and risks of new and investigational products.”
In our experience, organizations that modernize now can reduce that burden, create stronger internal controls, and give teams the support they need before small workflow issues become much larger problems.
How TrialAssure helps
TrialAssure helps sponsors simplify registration and results disclosure through more than 15 years of expertise in this space and proprietary REGISTRY technology built specifically for transparency workflows.
TrialAssure REGISTRY helps teams:
- Streamline ClinicalTrials.gov submissions
- Reduce manual entry
- Improve consistency across source documents
- Track approvals and submission progress in one place
- Accelerate global registration and results reporting
WIth more than 3,000 registered clinical trials out of compliance, the FDA just gave the industry a clear reminder, and the teams that act now will be in a much stronger position when the next deadline arrives.
Request a demo of REGISTRY here.
Connect with a transparency expert and ask any questions you may have here.
